Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF

Abstract:
Catechol-based inhibitors of ERCC1-XPF endonuclease activity were identified from a highthroughput screen. Exploration of the structure-activity relationships within this series yielded compound 13, which displayed an ERCC1-XPF IC50 of 0.6 µM, high selectivity against FEN-1 and DNase I and activity in nucleotide excision repair, cisplatin enhancement and H2AX assays in A375 melanoma cells. Screening of fragments as potential alternatives to the catechol group revealed that 3-hydroxypyridones are able to inhibit ERCC1-XPF with high ligand efficiency, and elaboration of the hit gave compounds 36 and 37 which showed promising ERCC1-XPF IC50 values of <10 µM.
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Platinum-based chemotherapeutics such as cisplatin result in several forms of DNA damage, however their effectiveness can be limited by efficient DNA repair processes. The ERCC1-XPF complex, formed from the heterodimerization of excision-repair cross complementation group 1 (ERCC1) and xeroderma pigmentosum F (XPF), has structure-specific endonuclease activity and plays an essential role in the removal of platinum-DNA adducts by nucleotide excision repair (NER). 1 It is also involved in interstrand crosslink repair (ICR) and there is evidence that it is a good target for intervention in melanoma, ovarian, lung and other cancers.
1 Inhibition of ERCC1-XPF activity therefore represents an approach to potentially enhance the effectiveness of chemotherapeutic agents such as cisplatin, however very few inhibitors have been reported in the literature. 2 We sought to identify novel inhibitors of ERCC1-XPF using a high-throughput fluorescencebased in vitro endonuclease assay 3 and one of the hits obtained was compound 1 (Figure 1 ) with an IC50 value of approximately 30 µM and modest ligand efficiency. The catechol motif is present in known nuclease inhibitors 4 and although the dibromo-substitution and hydrazone motif were considered undesirable, 1 showed good selectivity for ERCC1-XPF in counterscreen assays against the nucleases FEN-1 and DNase I. 3 We therefore sought to explore whether it was possible to design out the unwanted features and gain additional potency while retaining good selectivity for ERCC1-XPF. Testing of initial analogues showed that the catechol group was required for inhibitory activity since mono-or di-methylation led to complete loss of activity. Catechols are known to be effective binders of metal ions, in particular magnesium and manganese; the activity of ERCC1-XPF is metal-dependent and the presence of Mn 2+ is required for substrate turnover in the biochemical assay. It was therefore our hypothesis that they could inhibit ERCC1-XPF via binding to a metal ion at the endonuclease active site. Synthesis and testing of early analogues showed that the removal of the two bromine atoms and methyl group (Table 1, compound 2) and replacing the hydrazone with an amide (3) were all well tolerated, and this led to an improvement in potency and ligand efficiency while retaining selectivity against FEN-1 and DNase I. Variation of the linker lengths on the righthand-side portion of the amide core suggested that benzyl was preferred (4). With the benzylic catechol in place, a range of groups on the left-hand side portion of the molecule were explored (Table 2) , with synthetic access through amide coupling. Replacing the aniline NH in 4 with carbon (6) or oxygen (7) both led to reductions in potency, and shortening the linker also led to losses in potency (8, 9) . However, the introduction of additional substituents allowed potency to be regained, such as methyl (10), 4-chloro (11) or 2-chloro (12). The 2,4-dichloro variant (13) was the most potent compound at 0.6 µM. The 4-methoxy compound (14) was less potent than the 4-chloro, and the larger cyclohexyl variant (15) was relatively well tolerated. Smaller alkyl groups such as isopropyl (16) and cyclopentyl (17) were weak, although the cyclohexylmethyl (18) displayed an IC50 value of just over 1 micromolar. The introduction of more polar or larger groups (19-23) did not lead to potency improvements relative to 13. Modifications to the right-hand side portion were explored (Table 3 ) via amide coupling with the 2,4-dichlorobenzyl group fixed: cyclisation (24) or N-methylation of the amide (25) did not significantly affect potency. Halogen substituents were added to the catechol ring to explore the effect of modifying the steric and electronic properties (26, 27) including tuning the pKa of the catechol OH groups, and although this was tolerated it did not improve potency. Alterations to the amide core were investigated (Table 4) : the sulfonamide 28 showed reduced potency in comparison with 13, whereas the reverse amide 29 was equipotent to the parent amide. The ureas (30, 31) and oxadiazole variants (32, 33) also showed weaker potency compared to 13. Next, the potential for modifying the catechol motif was explored; as the catechol represents a liability, especially with respect to oxidation, replacement was desirable. Previous data suggested that it would be necessary for an alternative group to have good metal-binding capability, so in order to identify catechol variants we screened a number of fragments with metal-binding capability in our biochemical assay, with the intention that these could then be merged with the existing left-hand side portion. This identified 5-bromo-3-hydroxypyridone 34 as a fragment with a promising IC50 of 24 µM and high ligand efficiency ( Figure 2) ; this fragment has recently been shown to inhibit the activity of an influenza endonuclease with a similar level of potency and bind through a metal-based interaction. However, when it was merged with the left-hand side portion of compound 13 to give 35, this compound showed very weak activity against ERCC1-XPF, suggesting that the fragment might be binding in a different way to the catechol. Instead we therefore sought to exploit the fragment by substituting at the available positions, and due to the relative lack of structural knowledge around the protein binding site a systematic approach was employed. Firstly, replacing the bromine with a 4-fluorophenyl group (Table 5 , 36) gave a gain in potency to less than 10 µM and the 3-pyrazole substituted variant 37 showed an IC50 of approximately 5 µM. A wider range of R3 variants were investigated and selected examples are shown in Table 5 ; although none showed improved potency compared to 37, three other variants were within 3-fold (38-40). Substitution at the alternative vectors R1, R2 or R4 appeared to be poorly tolerated (41-43). Compounds 13 and 36 were profiled in ADMET assays (Figure 3 ). Compound 13 showed relatively short mouse and human microsomal half-lives and acceptable permeability, whereas 36 showed a long half-life; both compounds were not toxic to Hep-G2 cells up to a compound concentration of 10 µM. Although the catechols and hydroxypyridones showed selectivity for ERCC1-XPF over FEN-1 and DNase I, catechols in particular can show PAINS effects 7, 8 and interfere with assays through non-specific mechanisms; therefore it was important to demonstrate binding to target using a biophysical method. The interaction of compounds 13 and 36 with ERCC1-XPF was examined by surface plasmon resonance (SPR). Compound 13 showed a KD of ~30 µM, weaker than the biochemical IC50, with relatively slow binding kinetics (Figure 4) . By contrast, the hydroxypyridone 36 showed fast binding kinetics and a KD of 3.5 µM, in good agreement with the biochemical IC50. Neither compound showed binding to a control protein included in the study. Compound 13 was profiled in three cell-based assays using A375 melanoma cells to measure 1) direct nucleotide excision repair (NER) using a recombinant GFP reporter assay, 3, 9 2) potentiation of cisplatin induced cell toxicity 10 and 3) immunofluorescence detection of H2AX, a marker of DNA damage.
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Firstly, in the NER assay, repair of UV damaged pEGFP plasmid was monitored following treatment with compound for 24 hours at concentrations of up to 60 µM. Compound 13 showed inhibition of NER with an IC50 of 15.6 µM ( Figure 5 ).
9
Figure 5. Compound 13 NER in A375 melanoma cell line transfected with UV damaged pEGFP and a luciferase reporter plasmid (pGL3) to control for transfection efficiency. The fluorescence read out generated as the pEGFP plasmid is repaired is normalized to both luciferase levels and readings for undamaged DNA to generate the DNA Repair Index. Inhibition of NER is detected at higher concentrations of compound, IC50=15.6 µM.
Secondly, compound 13 was profiled in a cisplatin combination assay 10 ( Figure 6a ). The compound alone showed a reduction in cell number at 4.96 and 10 µM (Figure 6b ), however at compound concentrations where no toxicity was observed with compound only, there was an enhancement of cisplatin activity up to 1.5-fold (PF50) as shown in the table in Figure 6 . Thirdly, compounds were assayed in a γH2AX foci assay which is a marker of DNA repair 11 ( Figure 7) . A delay in repair of γH2AX foci was observed after 6 hours post treatment of cells with cisplatin in combination with compound 13 as indicated by a right shift towards higher numbers of foci per cell. Compound 13 activity in a γH2AX foci imaging assay. γH2AX foci count in A375 cells pretreated with compound for 1h, exposed to 5 µM cisplatin for 1h and continued exposure to compound at 10 µM for 6h. Levels of γH2AX were quantified by immunofluorescence using a specific antibody (Millipore) and results analysed on an InCell 2000 High Content Imager (GE Healthcare). Relative cumulative frequency plots were used in order to visualize the shift in the response to cisplatin and compound treatment. Compound 13 causes a delay in DNA repair as illustrated by the rightward shift of the curve showing that cells contain larger numbers of foci. The combined treatment of cisplatin and compound 13 is significantly more than cisplatin alone (p=0.0012 by Sum of Squares F test of the EC50). Results are from 2 representative experiments (triplicate tests in each) and the error bars are SEM.
In summary, we have shown that compounds containing a catechol or a 3-hydroxypyridone motif inhibited ERCC1-XPF with sub-micromolar or low micromolar potency in the endonuclease biochemical assay and displayed high selectivity over the other two nucleases tested. Exemplars from both series showed binding to ERCC1-XPF by SPR, and the leading example compound 13 showed inhibition of DNA repair in A375 melanoma cells across three assay formats. Further studies are required to understand the binding mode and cellular mechanism of action of these compounds. 
